Who Should NOT Microdose GLP-1

The central myth of microdosing is that a smaller dose makes the drug's safety boundaries optional. It doesn't. A microdose of semaglutide or tirzepatide is still semaglutide or tirzepatide — the same molecule, working through the same biology, carrying the same FDA-label contraindications and warnings. Lowering the dose may soften some dose-related side effects, but it does not erase the people for whom these drugs are flatly contraindicated, and it does not make a GLP-1 agonist safe for everyone. This page lays out who should not microdose a GLP-1 drug, anchored to the actual FDA prescribing information rather than forum lore.

One caution before the list: because microdosing is almost always done with compounded product and do-it-yourself dosing, it adds risks on top of the drug's own — uncertain concentration, preparation errors, no prescriber screening you against the contraindications below. The microdosing-specific clinical literature is cautionary precisely for these reasons ¹. So "who should not microdose" is a stricter question than "who should not take a prescribed, monitored full dose," not a looser one.

Absolute contraindications: the boxed warning and the FDA label

These are not cautions to weigh — they are populations for whom the FDA label says the drug is contraindicated, at any dose.

Personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Both semaglutide (Wegovy) and tirzepatide (Zepbound) carry a boxed warning — the FDA's most serious — for thyroid C-cell tumors, based on dose-dependent thyroid C-cell tumors seen in rodents; the human relevance is not determined, but the label is unambiguous that the drugs are contraindicated in people with a personal or family history of MTC or with MEN2 ²³. A microdose does not lift a boxed-warning contraindication. If this is you or your family, the drug class is off the table — microdose or not.

Known hypersensitivity to semaglutide, tirzepatide, or any excipient in the product is also a labeled contraindication ². Serious hypersensitivity reactions have been reported with these drugs.

Pregnancy and trying to conceive. GLP-1 drugs are not recommended in pregnancy; the labels carry pregnancy warnings based on animal reproductive harm, and because of the long action of these drugs, manufacturers advise stopping well before a planned pregnancy ²³. Microdosing for "wellness" or appetite while pregnant, trying to conceive, or breastfeeding is exactly the off-label, unmonitored use this drug class is designed to avoid. There is also an emerging signal worth a clinician conversation: prepregnancy GLP-1 exposure has been studied for its relationship to hypertensive disorders of pregnancy in women with obesity and diabetes ⁴ — another reason this is a clinician decision, not a self-directed one.

Strong cautions: conditions where a GLP-1 is risky and needs a clinician

These aren't blanket "never," but they're populations where microdosing on your own — without screening, monitoring, or a prescriber — is a bad idea. The FDA label flags each as a warning.

A history of pancreatitis. Acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists, and the label directs discontinuation if pancreatitis is suspected ². Real-world data link GLP-1 agonists used for weight loss to elevated pancreatitis risk ⁵, and tirzepatide safety reviews flag pancreatitis as a class concern ⁶. If you've had pancreatitis, this is a conversation with a doctor, not a microdose you self-start.

Gallbladder or biliary disease. Acute gallbladder disease is a labeled warning ². Rapid weight loss itself raises the risk of gallstones and biliary disease ⁷, and tirzepatide safety analyses flag gallbladder and biliary events specifically ⁶. People with active gallbladder disease, or a history of it, need medical oversight.

Kidney problems and anything that causes dehydration. Acute kidney injury due to volume depletion is a labeled warning: GI side effects like vomiting and diarrhea can cause dehydration that worsens kidney function ². Even at a low dose, GI effects are mechanistic, not purely dose-dependent, so the dehydration pathway isn't eliminated by microdosing. People with kidney disease, or who can't reliably stay hydrated, should not improvise.

Severe gastrointestinal disease or gastroparesis. Severe GI adverse reactions are a labeled warning, and these drugs slow gastric emptying by design ². A large meta-analysis confirms GI adverse events are a defining feature of the class ⁸. People with severe pre-existing GI disease — including gastroparesis — are exactly who shouldn't add a motility-slowing drug without specialist input.

Type 1 diabetes, or diabetes treated with insulin/sulfonylureas, without supervision. These drugs can cause hypoglycemia when combined with insulin or insulin secretagogues, which is why the label addresses concomitant use ². Anyone on those medications needs a clinician adjusting them — not a self-managed microdose.

Scheduled surgery or anesthesia. Because GLP-1 drugs delay gastric emptying, the label warns about pulmonary aspiration during general anesthesia or deep sedation ². If you have a procedure coming up, this is a must-disclose-to-your-team item — a microdose you didn't mention is still a microdose your anesthesiologist needs to know about.

Why microdosing makes the screening problem worse, not better

A prescribed, monitored GLP-1 comes with a clinician who is supposed to screen you against every item above before you start. The do-it-yourself, compounded microdosing route frequently skips that screening — and adds its own hazards: uncertain product concentration, preparation errors, and unregulated sourcing that the pharmacovigilance data flag clearly ¹. So the people who "should not microdose" include not only those with the contraindications and cautions above, but anyone planning to source and dose without a qualified clinician checking them against this list. The lower dose doesn't compensate for the missing safety net.

The honest bottom line

If you have a personal or family history of medullary thyroid carcinoma or MEN2, a known hypersensitivity, or you're pregnant or trying to conceive, the FDA label says these drugs are contraindicated — and a microdose changes nothing about that ²³. If you have a history of pancreatitis, gallbladder or biliary disease, kidney problems, severe GI disease, insulin-treated diabetes, or an upcoming surgery, a GLP-1 needs real medical oversight, not a self-started microdose. "Smaller dose" is not a substitute for "right patient." When in doubt, the safe move is the boring one: get screened by a clinician before any GLP-1 touches your body, at any dose.

For the wider picture, see our pillar Microdosing GLP-1: what the evidence actually shows, the broader safety review is microdosing GLP-1 safe, and the compounded-supply risks in is compounded / microdosed GLP-1 safe. To understand who's actually doing this and why, read who's microdosing GLP-1. And if you've been screened and want to compare vetted, clinician-involved providers, see our GLP-1 microdose rankings hub.